Progyny (PGNY) Q4 2025 earnings review
Record Cash Flow and Margins Obscured by Decelerating Growth
Progyny wrapped up 2025 with strong profitability and a massive cash return to shareholders, but the top-line narrative is under pressure. Q4 revenue grew 6.7% YoY to $318.4M (21% excluding the roll-off of a large transition client), paired with an impressive 280-basis-point expansion in gross margin to 24.1%. Management aggressively repurchased 6.5 million shares for $160M, leaning into the company's $210M annual operating cash flow. However, looking ahead to 2026, the guidance suggests the core growth engine is decelerating. First-quarter 2026 revenue is guided to be virtually flat on a reported basis, and underlying core growth is stepping down from the ~20% level to roughly 9-13%.
🐂 Bull Case
Gross margin expanded significantly to 24.1% in Q4 (from 21.3% a year ago), demonstrating real operating leverage and care management delivery efficiencies despite the loss of a major client.
The business model is highly cash-generative, yielding $210.2M in full-year operating cash flow. Management is actively defending the stock, utilizing $160M of a new $200M buyback authorization in just a few months.
🐻 Bear Case
Even adjusting for the large client loss, core revenue growth is expected to decelerate from 21% in 25Q4 to an implied midpoint of ~11.2% in 26Q1. The hyper-growth phase appears to be cooling.
Pharmacy benefit services revenue actually shrank 1.1% YoY in Q4, a stark contrast to the 11% growth in the core Fertility segment, signaling potential headwinds in drug utilization or pricing.
⚖️ Verdict: ⚪
Neutral. The underlying profitability and cash flow generation are excellent, and the buyback provides a floor. However, the optics of flat reported Q1 growth, paired with a clear deceleration in the core 'ex-transition client' business and a contracting pharmacy segment, will likely cap multiple expansion until organic growth stabilizes.
Key Themes
Operating Efficiencies Driving Gross Margin Expansion
Gross margin has been a consistent bright spot, accelerating to 24.1% in Q4 from 21.3% in the prior year. Management attributes this to ongoing efficiencies realized in the delivery of care management services. The higher gross profit successfully offset increased investments in platform expansion and recent acquisitions, pulling Adjusted EBITDA margin up to 16.1%.
Pharmacy Benefit Segment Reversing
A notable divergence has emerged between Progyny's two main revenue streams. While Fertility benefit services grew a respectable 11% in Q4, Pharmacy benefit services revenue contracted by 1.1% YoY to $109.8 million. This represents a continuous deceleration throughout the year (from +9% in Q1 to negative in Q4), raising questions about drug pricing dynamics, mix shift, or utilization of associated treatments.
Aggressive Capital Returns Demonstrating Confidence
Supported by a record $210.2M in annual operating cash flow, management moved aggressively on capital returns. During Q4, they repurchased 3.3 million shares for $83.6M. To date, they have executed roughly $160M of the newly authorized $200M program (retiring approx. 6.5 million shares). This provides critical EPS support while top-line growth digests the large client transition.
Member Utilization Variability Embedded in Guidance
Management continues to manage expectations around member engagement, stating that 2026 guidance ranges reflect 'the potential for variability in member engagement.' Full-year 2025 female utilization ultimately landed at 1.04%, down from 1.07% in 2024. Q4 female utilization was stable YoY at 0.48%, but the ongoing need to buffer guidance against usage fluctuations indicates macro headwinds or shifting member behavior remain active risks.
Expanding Total Addressable Market & Service Offerings
Moving into 2026, Progyny anticipates growing its client base to approximately 600 clients, covering 7.2 million lives. Beyond client growth, they are actively launching their newest program tailored for the fully insured market and scaling recently acquired/introduced solutions (menopause, leave navigation, Progyny Global) to capture a broader portion of women's health spending.
Other KPIs
Accelerating. Up from $179.1M in FY24. The company has successfully maintained a targeted 75%+ conversion rate of Adjusted EBITDA to Operating Cash Flow. This cash engine leaves the company with $310.1M in cash/marketable securities and zero debt, even after aggressive stock buybacks.
Improving. The company's ongoing focus on revenue cycle management yielded an improvement of more than 8 days compared to the end of 2024, demonstrating stronger working capital execution and supporting the robust cash flow.
Guidance
Decelerating. Implies reported YoY growth of -1.6% to +2.5%. Even after adjusting for the $31.3M in revenue from the large transition client in Q1 2025, underlying core growth is projected at 9.0% to 13.4%, a material step down from the 21% core growth seen in 25Q4.
Decelerating. Implies full-year reported growth of 5.1% to 9.0% (and core growth of 9.3% to 13.3% excluding $48.5M from the transition client in 1H25). This marks the first time Progyny's core organic growth is settling into the low double-digits, reflecting the law of large numbers and a slower pipeline build noted earlier in the year.
Stable/Decelerating. The midpoint of $231.5M implies ~4.2% YoY growth from FY25's $222.1M. This growth rate is slower than the projected revenue growth rate, implying that the robust margin expansion seen in 2025 may flatten or slightly compress in 2026 as the company continues to invest in new products (fully insured market, global expansion).
Key Questions
Pharmacy Segment Contraction
Pharmacy benefit services revenue fell 1.1% YoY in Q4. Was this driven by lower drug utilization, pricing pressure, mix shifts toward lower-cost treatments, or the impact of the large transition client? How should we model the Pharmacy attachment rate for the 2026 cohort?
Core Growth Deceleration
Guidance implies core revenue growth (excluding the transition client) will decelerate from ~20% in 2025 to ~9-13% in 2026. How much of this is due to a slower selling season versus more conservative utilization assumptions?
Margin Trajectory in 2026
Gross margin expanded impressively in 2025 due to care management efficiencies. However, 2026 Adjusted EBITDA guidance implies slower growth than revenue. Are there specific investments or integration costs for the fully-insured market launch that will pressure margins next year?
Capital Allocation Strategy
With roughly $160 million of the $200 million buyback already executed, how does the Board view the authorization going forward? Will this be upsized in early 2026 given the strong cash flow profile and zero debt?